Clinical Trial of 2 doses of Avian Influenza A (H5N1) vaccine administered 3 vs 8 weeks apart

This study will evaluate an H5N1 vaccine approved for pandemic use in Canada, Arepanrix™, to better understand ideal timing of vaccine doses.  

Research in Canada and elsewhere has suggested that a longer time between doses of vaccines may give stronger protection. We will compare the immune response and safety of two doses of avian influenza vaccine given 3 weeks apart versus 8 weeks apart. 

H5N1 (also called bird flu or avian influenza) is a type of influenza (flu) virus that has been known since the 1990s. It mostly infects birds and other animals but can sometimes pass to people who are in close contact with infected animals.  

Because influenza viruses are capable of changing quickly, H5N1 could become better at passing between people. This makes it important to be prepared for the possibility of an outbreak or pandemic. 

This study is looking for volunteers who: 

• Are between the ages of 18-59 years old 
• Are in good health 
• Are not pregnant or planning to become pregnant within the study period 

Participation in this study involves: 

• A health assessment to check if you can participate  
• Six in-person clinic visits over 12 months (1 year) 
• Receiving an injection at three of the scheduled clinic visits – two doses of the study vaccine and one saline (saltwater) injection. 
• Having blood samples taken 
• Completing a diary card at home to record any symptoms after vaccination 
• A paper questionnaire about your opinion of the vaccine 

All other requirements and potential risks will be thoroughly outlined for you by the study team before you decide if you want to take part. 

Participants will be compensated for their time. 

This study is funded by the Canadian Immunization Research Network.